Navigation Links
Actavis Receives Approval of Levetiracetam Oral Solution in the U.S.
Date:1/21/2009

MORRISTOWN, N.J., Jan. 21 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Levetiracetam Oral Solution. Distribution of the product has commenced.

Levetiracetam Oral Solution is available in the 100mg/mL strength and is the generic equivalent of Keppra(R) Oral Solution by UCB, Incorporated. Levetiracetam Oral Solution is used in the treatment of partial onset seizures in adults and children with epilepsy. Annual U.S. sales of Keppra(R) Oral Solution were US$95.9 million for the 12 months ending September 2008 according to IMS Health data.

Commenting on the new approval, Doug Boothe, CEO of Actavis in the United States said:

"The approval of Levetiracetam Oral Solution demonstrates our continuing commitment to introduce new generic products to the marketplace, as well as highlights our expertise in developing and manufacturing a wide range of dosage forms. Actavis' drive to be a leader in generic pharmaceuticals is supported by one of the largest product development pipelines in the industry. "

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S.
2. Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
3. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
4. Actavis Extends Portfolio With Four New Products in the U.S.
5. Actavis Confirms its Patent Challenge of Kings Avinza(R)
6. Actavis Launches Amlodipine Tablets in the U.S.
7. Actavis Launches Carvedilol Tablets in the U.S.
8. Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award
9. Samplify Systems Receives Top Honors From Electronic Products and EDN Magazines
10. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
11. Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , ... December 09, 2016 , ... ... at The Pierre Hotel in New York, NY, on December 3rd, to benefit ... and physicians attended the annual event, which raised over $1 million - the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa Wound ... Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the ... hospitals and facilities have earned this distinction. This is the second time the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... vaccines market to grow at a CAGR of 6.83% during the ... the growth prospects of the global travel vaccines market for 2016-2020. ... from the sales of various vaccines administered to actively immunize meningococcal ...
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery ... 8.8% during the forecast period of 2016 to 2021. ... by 2021 from USD 18.21 billion in 2016. The ... rising incidences of sports related injuries and spinal problems, ... rising need of effective blood loss management. ...
Breaking Medicine Technology: